Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04263051 |
| Title | Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer (Optim-UCPVax) |
| Acronym | Optim-UCPVax |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Centre Hospitalier Universitaire de Besancon |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | FRA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| CHU of Besançon | Besançon | 250000 | France | Details | ||
| CHU Bordeaux | Bordeaux | France | Details | |||
| Centre Georges François Leclerc | Dijon | France | Details | |||
| Institut de Cancérologie Privé CCGM | Montpellier | France | Details | |||
| CH Mulhouse | Mulhouse | France | Details | |||
| CHU de Nîmes | Nîmes | France | Details | |||
| Institut Jean Godinot | Reims | France | Details | |||
| Institut de Cancérologie de l'Ouest | Saint-Herblain | France | Details |